Beyond the genomic characterization of RCC [115] and identification of signature mutations exclusive to RCC, affecting the VHL (52%) and PBRM1 (33%) genes [116], these data allowed for a comprehensive evaluation of associations among immune-, inflammation- and RCC-related genes [117]. This evidence concerns the gene PBRM1 and renal cell carcinoma.